ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Cogent Biosciences Inc

Cogent Biosciences Inc (COGT)

33,10
0,48
(1,47%)
Geschlossen 14 Juni 10:00PM
33,33
0,23
(0,69%)
Nach Börsenschluss: 1:59AM

Cogent Biosciences Inc (COGT) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
33,10
( 1,47% )
Gebot
24,67
Fragen
40,82
Volumen
1.480.145
32,33 Tagesbereich 33,53
6,8834 52-Wochen-Bereich 43,73
Marktkapitalisierung
Handelsende
32,62
Handelsbeginn
32,58
Letzte Trade
40
@
33.33
Letzter Handelszeitpunkt
Finanzvolumen
US$ 49.013.835
VWAP
33,1142
Durchschnittliches Volumen (3 Mio.)
US$ 2.132.633
Ausgegebene Aktien
170.911.934
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-12,42
Gewinn pro Aktie (EPS)
-2,51
Erlöse (LTM)
-
Nettogewinn (LTM)
-354,3M

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KI... Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Hauptsitz
Waltham, United States
Gegründet
-
Cogent Biosciences Inc is listed in the Healthcare sector of the NASDAQ with ticker COGT. The last closing price for Cogent Biosciences was US$32,62. Over the last year, Cogent Biosciences shares have traded in a share price range of US$ 6,8834 to US$ 43,73.

Cogent Biosciences currently has 170.911.934 shares in issue. The market capitalisation of Cogent Biosciences is US$5,66 billion. Cogent Biosciences has a price to earnings ratio (PE ratio) of -12.42.

COGT Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.732.2551745443332.3733.3330.93222246231.65411019CS
4-0.75-2.2156573116733.8535.9530.87243416732.93934774CS
12-1.34-3.8908246225334.4439.4130.87215803834.81559332CS
26-6.56-16.54059505839.6642.2530.87212883736.26592194CS
5225.97364.2356241237.1343.736.8834254221325.87700357CS
15620.98173.10231023112.1243.733.67175201016.57549508CS
26024.94305.6372549028.1643.733.67138476015.04658663CS

COGT - Frequently Asked Questions (FAQ)

What is the current Cogent Biosciences Inc share price?
The current share price of Cogent Biosciences Inc is US$ 33,10
How many Cogent Biosciences Inc shares are in issue?
Cogent Biosciences Inc has 170.911.934 shares in issue
What is the market cap of Cogent Biosciences Inc?
The market capitalisation of Cogent Biosciences Inc is USD 5,66B
What is the 1 year trading range for Cogent Biosciences Inc share price?
Cogent Biosciences Inc has traded in the range of US$ 6,8834 to US$ 43,73 during the past year
What is the PE ratio of Cogent Biosciences Inc?
The price to earnings ratio of Cogent Biosciences Inc is -12,42
What is the registered address of Cogent Biosciences Inc?
The registered address for Cogent Biosciences Inc is 275 Wyman Street, Waltham, Massachusetts, 02451
What is the Cogent Biosciences Inc website address?
The website address for Cogent Biosciences Inc is www.cogentbio.com
Which industry sector does Cogent Biosciences Inc operate in?
Cogent Biosciences Inc operates in the Biotechnology & Life Sciences sector

COGT Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen